OSL Stock Overview
A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OncoSil Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.007 |
| 52 Week High | AU$0.015 |
| 52 Week Low | AU$0.004 |
| Beta | 0.95 |
| 11 Month Change | -46.15% |
| 3 Month Change | -41.67% |
| 1 Year Change | -12.49% |
| 33 Year Change | -84.44% |
| 5 Year Change | -96.22% |
| Change since IPO | -96.50% |
Recent News & Updates
Recent updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky
May 24
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation
Feb 03Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?
Oct 20OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans
May 13OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years
Mar 21We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn
Jan 26How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?
Dec 04
Shareholder Returns
| OSL | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -22.2% | -6.0% | 1.5% |
| 1Y | -12.5% | 11.8% | 17.2% |
Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned 11.8% over the past year.
Return vs Market: OSL underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| OSL volatility | |
|---|---|
| OSL Average Weekly Movement | 16.3% |
| Life Sciences Industry Average Movement | 11.2% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: OSL's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: OSL's weekly volatility has decreased from 23% to 16% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Nigel Lange | www.oncosil.com |
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited Fundamentals Summary
| OSL fundamental statistics | |
|---|---|
| Market cap | AU$31.39m |
| Earnings (TTM) | -AU$11.91m |
| Revenue (TTM) | AU$1.57m |
20.1x
P/S Ratio-2.6x
P/E RatioIs OSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSL income statement (TTM) | |
|---|---|
| Revenue | AU$1.57m |
| Cost of Revenue | AU$1.51m |
| Gross Profit | AU$55.63k |
| Other Expenses | AU$11.97m |
| Earnings | -AU$11.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0027 |
| Gross Margin | 3.55% |
| Net Profit Margin | -761.07% |
| Debt/Equity Ratio | 0% |
How did OSL perform over the long term?
See historical performance and comparison